Have a feature idea you'd love to see implemented?
Let us know!
JAZZ Jazz Pharmaceuticals plc
Price (delayed)
$108.05
Market cap
$6.67B
P/E Ratio
17.21
Dividend/share
N/A
EPS
$6.28
Enterprise value
$11.09B
Jazz Pharmaceuticals plc is a biopharmaceutical company based in Ireland. It was founded in 2003. One of the company's most significant products is the United States Food and Drug Administration
Highlights
The P/E is 59% lower than the last 4 quarters average of 41.7
The company's EPS rose by 20% QoQ
Jazz Pharmaceuticals's quick ratio has decreased by 18% YoY but it has increased by 6% from the previous quarter
Key stats
What are the main financial stats of JAZZ
Market
Valuations
Earnings
Shares outstanding
61.75M
Market cap
$6.67B
Enterprise value
$11.09B
Price to earnings (P/E)
17.21
Price to book (P/B)
1.81
Price to sales (P/S)
1.74
EV/EBIT
19.61
EV/EBITDA
9.14
EV/Sales
2.84
Revenue
$3.91B
EBIT
$565.64M
EBITDA
$1.21B
Free cash flow
$1.04B
Per share
Balance sheet
Liquidity
EPS
$6.28
Free cash flow per share
$16.61
Book value per share
$59.69
Revenue per share
$62.18
TBVPS
$72.3
Total assets
$11.36B
Total liabilities
$7.6B
Debt
$5.77B
Equity
$3.76B
Working capital
$2.13B
Debt to equity
1.53
Current ratio
2.37
Quick ratio
1.72
Net debt/EBITDA
3.64
Margins
Efficiency
Dividend
EBITDA margin
31%
Gross margin
89.4%
Net margin
10.1%
Operating margin
14.3%
Return on assets
3.5%
Return on equity
10.8%
Return on invested capital
8%
Return on capital employed
5.8%
Return on sales
14.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
JAZZ stock price
How has the Jazz Pharmaceuticals stock price performed over time
Intraday
-2.77%
1 week
-5.74%
1 month
-0.94%
1 year
-17.55%
YTD
-12.15%
QTD
-3.02%
Financial performance
How have Jazz Pharmaceuticals's revenue and profit performed over time
Revenue
$3.91B
Gross profit
$3.5B
Operating income
$560.54M
Net income
$394.92M
Gross margin
89.4%
Net margin
10.1%
Jazz Pharmaceuticals's net income has increased by 19% QoQ
The company's net margin rose by 17% QoQ
The operating income rose by 8% since the previous quarter
The gross profit has grown by 8% YoY
Growth
What is Jazz Pharmaceuticals's growth rate over time
Valuation
What is Jazz Pharmaceuticals stock price valuation
P/E
17.21
P/B
1.81
P/S
1.74
EV/EBIT
19.61
EV/EBITDA
9.14
EV/Sales
2.84
The P/E is 59% lower than the last 4 quarters average of 41.7
The company's EPS rose by 20% QoQ
The price to book (P/B) is 25% lower than the 5-year quarterly average of 2.4 and 14% lower than the last 4 quarters average of 2.1
Jazz Pharmaceuticals's equity has increased by 7% YoY
The price to sales (P/S) is 38% less than the 5-year quarterly average of 2.8 and 13% less than the last 4 quarters average of 2.0
The revenue has grown by 3.9% YoY
Efficiency
How efficient is Jazz Pharmaceuticals business performance
The company's return on assets rose by 21% QoQ
The return on equity has increased by 17% since the previous quarter
JAZZ's ROIC is up by 10% QoQ
The company's return on sales rose by 7% QoQ
Dividends
What is JAZZ's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for JAZZ.
Financial health
How did Jazz Pharmaceuticals financials performed over time
The total assets is 50% greater than the total liabilities
The company's current ratio fell by 25% YoY but it rose by 4.4% QoQ
Jazz Pharmaceuticals's quick ratio has decreased by 18% YoY but it has increased by 6% from the previous quarter
The company's debt is 53% higher than its equity
Jazz Pharmaceuticals's equity has increased by 7% YoY
Jazz Pharmaceuticals's debt to equity has decreased by 7% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.